Freenome, Inc. FRNM
Regular-session close
After hours · Nov 19, 5:45 PM ET
- YTD
- -23.83%
- 1 year
- -7.67%
5D -1.27 (-11.55%)
- Market cap
- 1.11B
- Revenue (ttm)
- 217.86M
- Profit margin
- -50.83%
- EPS (ttm)
- -1.30
- Shares out
- 111.50M
- Forward P/E
- -3.97
- YTD return
- -23.83%
- 1-year return
- -7.67%
- 50-day average
- 13.60
- 200-day average
- 12.31
- Volume
- 875.40K
- Avg volume
- 835.42K
- Open
- 9.85
- Previous close
- 9.73
- Day's range
- 9.85 – 10.51
- 52-week range
- 9.73 – 17.11
- Beta
- 0.60
- Analysts
- Strong Buy
- Price target
- 18.00 (+81.4%)
- Earnings date
- Dec 2, 2026
Key statistics
- Enterprise value
- 850.46M
- Price / sales
- 5.08
- Price / book
- 2.29
- Revenue growth
- 17628.40%
- Total cash
- 429.97M
- Total debt
- 201.66M
- Return on equity
- -35.90%
Fundamental scorecard
7 of 25 checks passed on FRNM’s reported financials
7of 25 checks passed
- Value 1 of 5
- Growth 2 of 5
- Profitability 0 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 17.00
- Target (mean)
- 18.00
- Target (high)
- 21.00
- Strong buy0
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 2, 2026
Expected Dec 2, 2026. Consensus EPS estimate -0.195.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 2, 2026 | Dec 30, 2026 | 0.1375 | — | — | — |
| Nov 10, 2026 | Sep 30, 2026 | 0.1375 | 1.10 | +0.96 | +700.00% |
| Jul 15, 2026 | Jun 30, 2026 | -1.78 | -1.91 | -0.13 | -7.61% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 2026 | Guggenheim | init | — | Buy |
| Aug 18, 2026 | TD Cowen | init | — | Buy |
| Aug 17, 2026 | Jefferies | init | — | Buy |
| Aug 17, 2026 | BTIG | init | — | Buy |
About Freenome, Inc.
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- freenome.com
News
Freenome to Participate in the Piper Sandler 38th Annual Healthcare Conference
Freenome (NASDAQ:FRNM) Stock Has Average Target Price of $18.00 According to Analysts
Freenome Q3 Earnings Call Highlights
Freenome Q3 2026 Earnings Call Transcript UPDATE: Freenome Q3 Adj. EPS $1.10 Beats $0.41 Estimate, Sales $183.489M Beat $105.866M Estimate
Freenome Reports Third Quarter 2026 Financial Results
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought Freenome Unveils SimpleScreen Lung Enabling Patients To Be Screened For Lung And Colorectal Cancer Through Single Blood Draw, Using Two Independently Validated, Indication-Specific Tests
Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option
Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026
Your note
Sign in to keep a note on FRNM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTMAN MICHAEL SETH | Former | Conversion of Exercise of derivative security | Jul 19, 2026 | 0 |
| EDELMAN JOSEPH E | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jul 19, 2026 | 0 |
| MCKENNA MARK C | Former | Conversion of Exercise of derivative security | Jul 19, 2026 | 30,000 |
| PERCEPTIVE CAPITAL SOLUTIONS HOLDINGS | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jul 19, 2026 | 0 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jul 19, 2026 | 0 |
| SONG KENNETH M.D. | Former | Conversion of Exercise of derivative security | Jul 19, 2026 | 30,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 13.78% | 15,367,270 | 152.52M | Sep 29, 2026 |
| Perceptive Advisors Llc | 11.31% | 12,606,053 | 125.12M | Sep 29, 2026 |
| a16z Capital Management, L.L.C. | 5.00% | 5,571,599 | 55.30M | Sep 29, 2026 |
| Farallon Capital Management LLC | 3.35% | 3,733,757 | 37.06M | Sep 29, 2026 |
| Price (T.Rowe) Associates Inc | 2.74% | 3,055,038 | 30.32M | Sep 29, 2026 |
| ARK Investment Management, LLC | 2.50% | 2,787,707 | 27.67M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK Venture Fund | 1.81% | 2,019,291 | 20.04M | Jul 30, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 1.59% | 1,773,073 | 17.60M | Oct 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.36% | 397,340 | 3.94M | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 0.22% | 241,499 | 2.40M | Sep 29, 2026 |
| T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Global Stock Fd. | 0.21% | 238,855 | 2.37M | Jul 30, 2026 |
| Federated Hermes World Investment Series, Inc.-Federated Hermes Intl S | 0.12% | 137,000 | 1.36M | Sep 29, 2026 |
